{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:36:04Z","timestamp":1777952164090,"version":"3.51.4"},"reference-count":19,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"DOI":"10.2340\/ao.v65.45126","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:52:57Z","timestamp":1777895577000},"page":"375-378","source":"Crossref","is-referenced-by-count":0,"title":["SPRINTR: Swedish PRecision medicine Initiative for Novel Treatments and Research-towards efficient recruitment to clinical trials for prostate cancer"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6480-636X","authenticated-orcid":false,"given":"Karin","family":"Wel\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-0887","authenticated-orcid":false,"given":"Andreas","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"153869","unstructured":"Edsjo A, Russnes HG, Lehtio J, Tamborero D, Hovig E, Stenzinger A,"},{"key":"153870","doi-asserted-by":"crossref","unstructured":"et al. High-throughput molecular assays for inclusion in personalised oncology trials \u2013 state-of-the-art and beyond. J Intern Med. 2024;295(6):785\u2013803.","DOI":"10.1111\/joim.13785"},{"key":"153871","doi-asserted-by":"crossref","unstructured":"Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn. 2010;12(4):409\u201317.","DOI":"10.2353\/jmoldx.2010.090155"},{"key":"153872","doi-asserted-by":"crossref","unstructured":"Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Ozguroglu M, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025;31(12):4109\u201318.","DOI":"10.1038\/s41591-025-03961-8"},{"key":"153873","doi-asserted-by":"crossref","unstructured":"Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53\u201368.","DOI":"10.1016\/S0302-2838(26)00576-2"},{"key":"153874","doi-asserted-by":"crossref","unstructured":"Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol. 2005;48(4):577\u201383.","DOI":"10.1016\/j.eururo.2005.05.016"},{"key":"153875","doi-asserted-by":"crossref","unstructured":"Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008;21(11):1371\u20138.","DOI":"10.1038\/modpathol.2008.104"},{"key":"153876","doi-asserted-by":"crossref","unstructured":"Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, et al. Transcriptomic heterogeneity in high-risk prostate cancer and implications for extraprostatic disease at presentation on prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2023;6(2):224\u20137.","DOI":"10.1016\/j.euo.2023.02.009"},{"key":"153877","doi-asserted-by":"crossref","unstructured":"Spyratou V, Freyhult E, Bergh A, Thellenberg-Karlsson C, Wikstrom P, Welen K, et al. Ki67 and prostate specific antigen are prognostic in metastatic hormone naive prostate cancer. Acta Oncol. 2023;62(12):1698\u2013706.","DOI":"10.1080\/0284186X.2023.2254480"},{"key":"153878","doi-asserted-by":"crossref","unstructured":"Thysell E, Kohn L, Semenas J, Jaremo H, Freyhult E, Lundholm M, et al. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol. 2022;16(4):846\u201359.","DOI":"10.1002\/1878-0261.13158"},{"key":"153879","doi-asserted-by":"crossref","unstructured":"Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, et al. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol. 2019;13(8):1763\u201377.","DOI":"10.1002\/1878-0261.12526"},{"key":"153880","doi-asserted-by":"crossref","unstructured":"Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, et al. Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Cancer Res. 2019;25(8):2450\u20137.","DOI":"10.1158\/1078-0432.CCR-18-3121"},{"key":"153881","unstructured":"Genomic Medicine Sweden. GMS560: a broad targeted NGS gene panel for comprehensive genomic profiling of solid tumors [Internet]. 2023 [cited 2026 Mar 02]. Available from: https:\/\/genomicmedicine.se\/wp-content\/uploads\/2023\/11\/GMS560_synopsis.pdf"},{"key":"153882","doi-asserted-by":"crossref","unstructured":"Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjalm-Eriksson M, et al. An expression signature at diagnosis to estimate prostate cancer patients\u2019 overall survival. Prostate Cancer Prostatic Dis. 2014;17(1):81\u201390.","DOI":"10.1038\/pcan.2013.57"},{"key":"153883","unstructured":"Edsjo A, Friedman M, Rosenquist R. [Genomic Medicine Sweden \u2013 a national initiative for the broad introduction of precision medicine in Swedish healthcare]. Lakartidningen. 2021;118:21023."},{"key":"153884","unstructured":"Genomic Medicine Sweden. Genomic Medicine Sweden, GMS, is paving the way for improved diagnostics, care and treatment [Internet]. 2026 [cited 2026 Apr 12]. Available from: https:\/\/genomicmedicine.se\/en\/"},{"key":"153885","unstructured":"Clinical Trials Sweden. Clinical studies Sweden \u2013 development and support of clinical studies in healthcare [Internet]. 2026 [cited 2026 Mar 15]. Available from: https:\/\/kliniskastudier.se\/english"},{"key":"153886","unstructured":"Biobank Sweden. Biobank Sweden \u2013 a national infrastructure for biobanking [Internet]. 2026 [cited 2026 Apr 12]. Available from: https:\/\/biobanksverige.se\/en\/a-national-infrastructure-for-biobanking\/"},{"key":"153887","unstructured":"European Commission. EUnetCCC \u2013 European network of Comprehensive Cancer Centres [Internet]. 2026 [cited 2026 Apr 12]. Available from: https:\/\/health.ec.europa.eu\/non-communicable-diseases\/cancer\/europes-beating-cancer-plan-eu4health-financed-projects\/projects\/eunetccc_en"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45126\/53766","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45126\/53766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:53:08Z","timestamp":1777895588000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":19,"URL":"https:\/\/doi.org\/10.2340\/ao.v65.45126","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}